TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| China Nuokang Bio-Pharmaceutical Inc. to Report First Quarter 2010 Financial Results (GlobeNewswire) BEIJING -- China Nuokang Bio-Pharmaceutical Inc. , a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products, today announced that the Company plans to release first quarter financial results on Wednesday, June 2, 2010, after market close. us.rd.yahoo.com |
Jury Still Out on Exelixis's Long Term Potential Ohad Hammer submits:Exelixis (EXEL) came under a lot of pressure recently and the stock is now trading near its 52 week low following two unrelated events that took place last month. In late June, the company announced the resignation of its CEO, George Scangos, who was appointed as Biogen Idec’s (BIIB) CEO. Earlier that month, the company announced BMS (BMY) decided to give back rights for Exelixis’ flagship product, XL184. Adding to the pressure are interesting but not stellar clinical results for some of the company’s compounds at ASCO and potentially an additional partnership termination. With respect to future development of XL184, Exelixis is in a delicate position. On the one hand, it would like the drug to have an aggressive development program, which requires a large partner. On the other, it might want to wait until it generates more data, due to the bad sentiment around a compound that has been abandoned twice by two large pharmas (BMS and GSK). XL184 faces some meaningful potential value creation events in the coming 12 months, including data that could support FDA approval in a niche indication. The company will therefore have to find the optimal point in time for a licensing deal that will not slow down the development process while enabling it to increase the value of the compound.Complete Story » seekingalpha.com |
New Superbug Spurs Warning Some bacteria have learned a new way to deactivate the antibiotics that usually kill them, raising concerns about a novel wave of drug-resistant "superbugs" that travelers could spread world-wide. online.wsj.com |
China Cord Blood Corporation Updates Status Regarding Share Repurchase Program [PR Newswire] - China Cord Blood Corporation , the first and largest cord blood bank operator in China, today announced that since the authorization of the stock repurchase program on September 15, 2010, the Company has repurchased approximately 309,000 ordinary shares for approximately US$1.6 million through October 6, 2010 at an average price per share of US$5.32. Â This amount represents approximately 10.7% of the total repurchase program authorized by CCBC's Board of Directors, with approximately US$13.4 million remaining in the Company's buyback authorization for repurchase prior to September 2011. us.rd.yahoo.com |
Long Odds Seen For Diet Drugs The FDA's rejection of the weight-loss drug lorcaserin highlights the difficulty in developing medications that would likely be taken by millions of people, many of whom don't have any current health problems. online.wsj.com |